Prestige Consumer Healthcare Reports 6.5% Revenue Growth but Declines in Net Income and Gross Profit

Prestige Consumer Healthcare Inc. reported total revenues of $265.7 million for the three months ended June 30, 2026, marking a 6.5% increase from $249.5 million in the same period last year. The growth was primarily driven by the acquisition of the OTC Wellness Business, which contributed $5.9 million in revenue since its acquisition on June 12, 2026. However, net income decreased to $29.2 million, down from $47.5 million in the prior year, reflecting a decline of 38.5%. This resulted in earnings per share of $0.61, compared to $0.96 in the previous year.

The company's gross profit also saw a decline, falling to $136.2 million from $140.3 million, a decrease of 3.0%. The gross profit margin decreased to 51.3% from 56.2%, attributed to increased costs associated with the integration of the Pillar5 facility and amortization of inventory fair value step-up related to the OTC Wellness Business acquisition. Operating income was reported at $52.5 million, down from $71.8 million, reflecting a significant increase in operating expenses, which rose to $83.7 million from $68.6 million, largely due to acquisition-related costs.

In terms of strategic developments, Prestige completed the acquisition of the OTC Wellness Business for $1.045 billion, funded through a new term loan. This acquisition aligns with the company's strategy to expand its portfolio in the over-the-counter healthcare market. Additionally, the company acquired Pillar5 Pharma in December 2025, further enhancing its capabilities in sterile ophthalmic manufacturing. The company is also evaluating the acquisition of LaCorium Health, which was completed on July 1, 2026, for approximately $150 million.

Operationally, Prestige reported a total of 47,374,522 shares of common stock outstanding as of July 31, 2026. The company has seen a shift in consumer purchasing patterns, with an increase in online sales, which has influenced its distribution strategies. The company continues to face challenges related to supply chain disruptions and rising input costs, which have impacted product availability and pricing. The company anticipates that these economic conditions may continue to affect its operations and financial performance in the near term.

Looking ahead, Prestige Consumer Healthcare Inc. remains focused on integrating its recent acquisitions and optimizing its operations to enhance profitability. The company expects to navigate the current economic uncertainties while leveraging its strong brand portfolio and distribution network to drive growth. Management is committed to maintaining compliance with its debt covenants and believes that its cash flow from operations, along with existing credit facilities, will be sufficient to support its operational and capital needs in the coming year.